MTC cells express high amounts of CEA and encouraging therapeutic results have been obtained using anti-CEA pretargeted 131I-di-DTPA peptide in 2 phase I/II and 1 phase II clinical trials [6,22,23,24]. Here, CEACAM5 is linked to medullary thyroid gland carcinoma.